|
KMID : 0377619710210060493
|
|
Korean Jungang Medical Journal
1971 Volume.21 No. 6 p.493 ~ p.496
|
|
|
Clinical Observations with Chymotrypsin(Chymoral)
|
|
|
|
|
Abstract
|
|
|
Since Kunitz and Northrop first crystallized trypsin and chymotrypsin a great number of reports have confirmed that proteolytic enzymes have therapeutic and prophylactic effects, including anti-inflammatory, anti-edemic, thrombolytic, mucolytic, fibrinolytic, and "healing".
Because of this range of benefits, new uses for proteolytic enzymes are continually being explored.
It was the purpose of this investigation to determine whether the chymotrypsin {Chymoral) is effective in anti-inflammatory, and anti-edemic remedies, enhances the action of antibiotics, and causes the complications locally or systemically after administration.
The study was investigated the effects of Chymoral clinically in 64 random patients in orthopedic field admitted to Severance Hospital.
They were divided into two, a treated group and a non-treated group.
The treated group, who were given Chymoral for 7 days, contains 38 patients which included 10 operation cases and 29 cases using with antibiotics.
The non-treated group, who were not treated with any Chymoral, contains 26, patients which included 5 operation cases and 18 cases using antibiotics alone. Close observation of 64 hospitalized patients for a minimum 14 days permits the conclusion that Chymoral is a valuable adjunctive drug in controlling inflammation. Specifically, Chymoral reduces or prevents traumatic and surgical edema and hematoma, accelerates absorption of blood and lymph effusion, reduces pain, promotes wound healing, and may enhance or augment the action of antibiotics.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|